Join Dr. Ke Li (UCSF) and Dr. Garrett Rettig (IDT) to explore advances in personalized gene-edited cell therapies. Learn about prospects for a CRISPR-on-Demand platform for rare genetic diseases, non-viral T cell manufacturing, and ultra-large DNA knock-in. Discover how gRNA grade and purity influence editing potency and off-target analysis, with comparability data supporting the use of early screening results to help inform later stages of therapeutic development.